$AIMJul 7, 2026, 1:03 PMAI processed
AIM CEO: DURIPANC Phase 2 enrollment/dosing complete; encouraging interim signals for Ampligen
AI Summary
AIM ImmunoTech released a CEO Corner in which CEO Thomas Equels said the DURIPANC Phase 2 trial of Ampligen (rintatolimod) plus AstraZeneca’s durvalumab has completed patient enrollment and dosing and has shown encouraging interim clinical observations with continued favorable safety. The company said Phase 3 planning is underway and highlighted collaborations with AstraZeneca and Erasmus Medical Center and IP expansion, but provided no primary endpoint data or timelines and emphasized the statements are preliminary and forward‐looking.
Positives
- DURIPANC Phase 2 trial enrollment and dosing completed for Ampligen + durvalumab
- Company reports encouraging interim clinical observations and continued favorable safety
- Phase 3 planning is underway and AIM notes strategic collaboration with AstraZeneca and Erasmus Medical Center
Negatives
- No primary endpoint results, quantitative efficacy, or survival data disclosed
- No timing provided for primary endpoint evaluation or Phase 3 start
- Company cautions results are preliminary and forward‑looking; additional testing required